16 February 2021 | 09:56am
StockMarketWire.com - contract research organization Fusion Antibodies said it had appointed Dr Richard Jones as chief executive officer, replacing Dr Paul Kerr.
Kerr would become a consultant to the company so that he can continue to support the Company going forward, the company said.
Concurrent with his stepping down from the board, Kerr was exercising 125,000 options over ordinary shares of 4 pence each in the company at an exercise price of 4 pence per option, it added.
At 9:56am: [LON:FAB] Fusion Antibodies Plc Ord 4p share price was 0p at 132.5p
Story provided by StockMarketWire.com
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
From Sunday sermon to the strip club: The duality of Mistah F.A.B.
FacebookTwitterEmail
Dope Era clothing shop in Oakland, founded by rapper Mistah F.A.B. in 2011.Patricia Chang/Special to SFGATE
The back office of the Dope Era clothing store in Oakland is like a teenager’s dream, filled with NBA Jam and Street Fighter II arcade machines and a classic NES piled underneath clutter that looks like homework the dog ate. It seems like a place that’s more play than work, and to watch Mistah F.A.B.’s wildly popular Instagram videos featuring him goofing off with his uncle Ernest “Unc” Holloway, you might think that’s the case.
Hits: 624
SAN FRANCISCO, CA, USA and SUZHOU, China I February 08, 2021 I Innovent Biologics, Inc. ( Innovent ) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that the first patient has been successfully enrolled and dosed in the randomized, open-label, phase III, multicenter clinical study (NCT04720716) evaluating its IBI310 (anti CTLA-4 monoclonal antibody) in combination with TYVYT® (sintilimab injection) for the first-line treatment of patient with advanced hepatocellular carcinoma (HCC).
In recent years, immune checkpoint inhibitors have brought new hope to HCC patient population with acceptable safety and encouraging efficacy. NCT04720716 is a randomized, open-label, controlled, multicenter phase III study evaluating the efficacy and safety of IBI310 in combination with TYVYT® (sintilimab injection) for